Why Is Humana (HUM) Down 8.5% Since Last Earnings Report?

Core Viewpoint - Humana's recent earnings report indicates a mixed performance with a significant adjusted loss per share, despite revenue growth driven by its CenterWell unit, raising questions about future performance and investor sentiment [2][3][21]. Financial Performance - Humana reported a Q4 2025 adjusted loss of $3.96 per share, which was narrower than the consensus estimate of a loss of $4.01 per share but wider than the prior year's loss of $2.16 per share [2]. - Adjusted revenues increased by 11.8% year over year to $32.6 billion, surpassing the consensus mark by 2.4% [2]. - Premiums totaled $30.9 billion, up 11.3% year over year, exceeding both the consensus estimate of $30.2 billion and the internal estimate of $29.8 billion [4]. - Total operating expenses rose by 12% year over year to $33.3 billion, higher than the internal estimate of $31.8 billion [5]. Segment Performance - The Insurance segment's adjusted revenues increased by 11.3% year over year to $31.3 billion, driven by improved per-member premiums and an expanding customer base [6]. - CenterWell recorded revenues of $6 billion, a 16.2% year-over-year increase, benefiting from higher revenues in pharmacy and primary care businesses [8]. Membership and Operating Metrics - Total medical membership in the Insurance segment fell by 8.2% year over year to 15 million, below the consensus estimate of 15.1 million [7]. - The benefit ratio for the quarter was 93%, deteriorating by 150 basis points year over year [5]. Cash Flow and Capital Deployment - Humana ended Q4 with cash and cash equivalents of $4.2 billion, an increase of 89.1% from the end of 2024 [10]. - The company generated net cash from operations of $921 million in 2025, a decline of 68.9% from the previous year [11]. - Humana repurchased shares worth $151 million and paid dividends of $430 million during 2025 [12]. Full-Year and Future Outlook - For 2025, adjusted revenues reached $129.8 billion, a 10.7% year-over-year growth, while adjusted EPS rose by 5.7% to $17.14 [13]. - For 2026, revenues are projected to be at least $160 billion, indicating a 23.4% increase from 2025, with adjusted EPS expected to decline by 47.5% to at least $9.00 [14][15]. - Management anticipates growth in Individual Medicare Advantage membership by around 25% in 2026 [15]. Market Position and Competitor Performance - Humana's stock has seen a downward trend in estimates since the earnings release, with a Zacks Rank of 3 (Hold), suggesting an in-line return in the near term [21]. - In comparison, Molina, a competitor in the same industry, reported a revenue increase of 8.3% year over year, but has a Zacks Rank of 5 (Strong Sell) due to negative estimate revisions [22][23].